$GERN Company News Baker Hughes, Halliburton gain on

New Post Public Reply Private Reply Replies (0) Message Board

Dec 7, 2014 at 10:58 PM

$GERN Company News

Baker Hughes, Halliburton gain on potential merger; Fossil in red 10:07 a.m. Nov. 14, 2014 - Sue Chang
Looming $40 crude and how to vape your way to profits 5:47 a.m. Nov. 14, 2014 - Shawn Langlois
Baker Hughes shares rise on possible buyout 6:02 p.m. Nov. 13, 2014 - Wallace Witkowski
Herbalife shares drop after hours as earnings disappoint 6:58 p.m. Nov. 3, 2014 - Wallace Witkowski
Geron's stock soars after FDA lifts hold on new drug application 7:48 a.m. Nov. 3, 2014 - Tomi Kilgore
Geron's stock jumps 35% premarket after FDA lifts hold on new drug application 7:35 a.m. Nov. 3, 2014 - Tomi Kilgore
FDA places hold on Geren's Imetelstat application 7:25 a.m. March 12, 2014 - MarketWatch.com
Charting the latest market whipsaw 10:59 a.m. Nov. 11, 2013 - Michael Ashbaugh
Oracle active, Geron shares fall after hours 6:06 p.m. Dec. 3, 2012 - Carla Mozee
Geron to discontinue brain-cancer drug development 4:38 p.m. Dec. 3, 2012 - MarketWatch.com
BioTime offers equity stake for Geron assets 8:47 a.m. Oct. 18, 2012 - MarketWatch.com
Monday’s biggest gaining and declining stocks 1:42 p.m. Sept. 10, 2012 - MarketWatch
Geron ends breast cancer study of Imetelstat 7:06 a.m. Sept. 10, 2012 - MarketWatch.com
Stocks to Watch Friday: Splunk, Zumiez, Pandora 3:59 p.m. Aug. 30, 2012 - David B. Wilkerson
Thursday’s biggest gaining and declining stocks 3:31 p.m. Aug. 30, 2012 - MarketWatch
Geron climbs 11% on analyst rating 9:56 a.m. Aug. 30, 2012 - Val Brickates Kennedy
Tuesday’s biggest gaining and declining stocks 5:37 p.m. Nov. 15, 2011 - Kate Gibson
Financial uncertainty nixed Geron stem cell work 2:09 p.m. Nov. 15, 2011 - MarketWatch.com
Stocks to watch Friday: Global Crossing, Clarcor 5:42 a.m. Sept. 30, 2011 - MarketWatch
Court upholds stem-cell research funding: reports 10:46 a.m. July 27, 2011 - Val Brickates Kennedy

Geron (GERN) Stock: Moving Average Crossover Alert - Tale of the Tape 9:47 a.m. Dec. 5, 2014 - Zacks.com
BioTime Harnesses Geron's Stem Cell Technology And Its Founder; Is That Enough To Survive The Biotech Revolution? 10:51 a.m. Dec. 3, 2014 - Seeking Alpha
Geron (GERN) Showing Signs Of A Dead Cat Bounce Today 10:10 a.m. Nov. 26, 2014 - TheStreet.com
Strong On High Relative Volume: Geron (GERN) 10:01 a.m. Nov. 21, 2014 - TheStreet.com
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog 11:23 a.m. Nov. 19, 2014 - Zacks.com
Can the Rally in Geron (GERN) Shares Continue? - Tale of the Tape 8:43 a.m. Nov. 19, 2014 - Zacks.com
Incyte Building Blockbuster Drug One Disease At A Time 2:58 p.m. Nov. 17, 2014 - Investors Business Daily
Geron (GERN) Stock Surges Following Johnson & Johnson Licensing Deal 10:40 a.m. Nov. 17, 2014 - TheStreet.com
Strength Seen in Geron (GERN): Stock Surges 19.5% - Tale of the Tape 9:25 a.m. Nov. 17, 2014 - Zacks.com
Geron Collaborates with J&J for Imetelstat - Analyst Blog 6:00 p.m. Nov. 14, 2014 - Zacks.com
Geron's Short Squeeze Is Here 3:40 p.m. Nov. 14, 2014 - Seeking Alpha
Stock Market Today: Stocks Mixed as Retail Sales Climb, House OKs Keystone Pipeline 3:36 p.m. Nov. 14, 2014 - TheStreet.com
Midday Gainers From November 14: Geron, Pandora Media, Bitauto, IAMGOLD 11:44 a.m. Nov. 14, 2014 - benzinga.com
What Licensing Imetelstat Will Mean for Geron 10:45 a.m. Nov. 14, 2014 - 247WallSt.com
Geron (GERN) Is Today's Pre-Market Mover With Heavy Volume Stock 9:04 a.m. Nov. 14, 2014 - TheStreet.com
Morning Market Movers 8:39 a.m. Nov. 14, 2014 - benzinga.com
Benzinga's Top #PreMarket Gainers 7:03 a.m. Nov. 14, 2014 - benzinga.com
Geron wins deal to develop blood disorder drug, could get $935M 5:55 p.m. Nov. 13, 2014 - Seeking Alpha
Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson 4:34 p.m. Nov. 13, 2014 - TheStreet.com
Geron's Risk/Reward Profile Improves As Near-Term Uncertainty Ends 1:06 p.m. Nov. 7, 2014 - Seeking Alpha

Geron to Host Analyst and Investor Meeting on December 8 9:31 p.m. Dec. 5, 2014 - Thomson Reuters ONE
Geron Announces Publication of Preclinical Data on Imetelstat Activity in Acute Myelogenous Leukemia 4:16 p.m. Dec. 4, 2014 - Thomson Reuters ONE
Geron to Present at the 26th Annual Piper Jaffray Healthcare Conference 4:16 p.m. Nov. 26, 2014 - Thomson Reuters ONE
Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA 9:00 a.m. Nov. 18, 2014 - PR Newswire - PRF
Geron to Present at the Stifel Healthcare Conference 4:16 p.m. Nov. 14, 2014 - Thomson Reuters ONE
Geron Announces Global Strategic Collaboration with Janssen to Develop and Commercialize Imetelstat 4:16 p.m. Nov. 13, 2014 - Thomson Reuters ONE
Geron Announces Presentations at American Society of Hematology Annual Meeting 9:15 a.m. Nov. 6, 2014 - Thomson Reuters ONE
Geron Announces Removal of Full Clinical Hold on Imetelstat IND 7:31 a.m. Nov. 3, 2014 - Thomson Reuters ONE
Biotech Equities Technical Analysis - ARIAD Pharma, Novavax, Galena Biopharma, Geron, and Celldex Therapeutics 7:40 a.m. Oct. 15, 2014 - PR Newswire - PRF
GERON SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors In Geron Corporation's January 2014 Offering To Contact The Firm 3:00 p.m. Oct. 10, 2014 - PR Newswire - PRF
Biotech Equities Technical Review -- Celldex Therapeutics, Synthetic Biologics, Geron, Catalyst Pharmaceutical Partners, and NPS Pharmaceuticals 8:15 a.m. Sept. 8, 2014 - PR Newswire - PRF
Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 6:00 a.m. Aug. 21, 2014 - PR Newswire - PRF
Geron Corporation Reports Second Quarter 2014 Financial Results 3:06 p.m. Aug. 11, 2014 - Thomson Reuters ONE
Geron to Assume Sponsorship of Myelofibrosis IST and IND 6:30 a.m. Aug. 5, 2014 - Thomson Reuters ONE
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma 8:00 a.m. Aug. 1, 2014 - PR Newswire - PRF
Geron Announces Conference Call to Discuss Second Quarter 2014 Financial Results 6:31 a.m. July 30, 2014 - Thomson Reuters ONE
Stock Watchout on Biotech Industry -- Research on ARIAD Pharma, Geron, Seattle Genetics, and Sarepta Therapeutics 6:30 a.m. June 26, 2014 - PR Newswire - PRF
Sales, Clinical Hold Removal, Trial Initiations, and Committee Recommendations - Analyst Notes on Geron, Zalicus, Northwest Biotherapeutics, Progenics and TG Therapeutics 4:30 a.m. June 17, 2014 - PR Newswire - PRF
Geron Reports Removal of Partial Clinical Hold on Myelofibrosis IST 4:01 a.m. June 12, 2014 - Thomson Reuters ONE
Intersect ENT Announces Appointment of Chief Financial Officer Jeryl Hilleman 7:03 a.m. June 4, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FIBRA Prologis Posts Strong Q3 2026 Results Amid Market Trends

Decoding FIBRA Prologis' Latest Numbers Never a dull moment in industrial real estate, folks—and FIBRA Prologis (BMV:FIBRAPL 14) just dropped its third quarter earnings results for 2026, lighting a fire in its trajectory. On the surface, their numbers seem to belt out a victory anthem, but let's peel back the layers to understand what truly hums under the hood. A...

GALY Expands Cocoa Operations US, UAE in 2026

The Evolution of GALY's Cocoa Strategy Alright, let's talk chocolate—a staple that somehow turned into high-tech business news. GALY is stepping up its game big time, pushing its cultured cocoa front into both the U.S. and the UAE. If you ask me, it's a smart move, adding some resilience to the cocoa supply chain that otherwise dances on the whims of Mother Nature. GALY...

LogiSense Secures Top Spot in 2026 Billing Solutions Guide

LogiSense Gets High Marks in MGI Research Guide Well, here we go. LogiSense is making waves in the enterprise billing scene, snagging a top-five spot in MGI Research's 2026 Agile Billing Top 50 Buyer's Guide. The Kitchener-based outfit has been recognized not just for its strength in handling billing volumes, but for its top-notch capability in solution strength. Their...

Workday's $2.5B Notes Move: What's the Play?

Workday's Strategic Financial Maneuver When a company like Workday starts shaking the trees for $2.5 billion through a senior notes offering, you better believe traders like me are perking up and paying attention. We're talking a registered public offering, no less, which isn't peanuts. With such a substantial move, it's clear Workday (NASDAQ: WDAY) is setting its sights...

TIER IV and TUM Drive Level 4 Autonomous Cars

Autonomous Driving Gets a German Boost Well folks, looks like the autonomous vehicle scene is hitting the autobahns with more horsepower than ever before. Today’s chatter is all about how TIER IV and the Technical University of Munich (TUM) have teamed up, tapping into the grid as they ride the waves of cutting-edge NVIDIA tech. The Sparks Under the Hood: NVIDIA...

California Contractors Honored for Safety Commitment

Commitment to Safety in the Construction Industry When it comes to construction, safety isn’t an afterthought—it’s woven into the very fabric of every project. The 39th Annual Construction Safety Excellence Awards by the Associated General Contractors of California (AGC of California) pits a spotlight on those embodying this ethos. Industry Leaders in Safety Held on...

NAFTZ Conference Spotlights Trade Zones Amid Policy Shifts

The story ripping through San Diego at the NAFTZ conference? America's trade zones aren't just back in the game—they're smarter and sharper amid the trade policy chaos. The National Association of Foreign-Trade Zones hit a record with 600 attendees, and it's a damn clear sign that these zones are hot on the radar. Policy Shifts and Knuckle-Down Discussions These zones...

Duolingo Faces Class Action: Investors Brace for Impact

Going Beyond Language Learning Hype Listen, it's not every day you wake up to a lawsuit calling out one of those seemingly indestructible tech darlings. Well, Duolingo (NASDAQ: DUOL) is caught in the crosshairs now. They face allegations of pulling the wool over investors' eyes about their monetization and growth tactics. If you snapped up some stock between May 2, 2025,...

Haystack Expands MCP to Boost AI Intranet Workflow

Bridging the Intranet and AI: A Game Changer? You ever feel like your company's intranet is a black hole, swallowing all the information you need before spitting it back out in a chaos of outdated pages and broken links? Well, Haystack aims to clear that fog with their Model Context Protocol (MCP) server. And starting October 26, the game takes a leap forward. Now, not...

Lazard's Q3 2026: Surging Revenue, Waning Net Income

Breaking Down the Numbers Lazard just dropped its Q3 2026 earnings report, and you can smell both optimism and caution in the air. Sure, $814 million in net revenue isn’t anything to sneeze at, especially when it’s a neat 9% jump from last year’s $748 million. Adjusted figures were a whisker away at $805 million. But dig deeper, and things get a tad less rosy—net...